Strategies to Treat Osteoporosis Following a Fragility Fracture (OPTIMUS)
This study has been completed.
Université de Sherbrooke
Merck Sharp & Dohme Corp.
Procter and Gamble
Eli Lilly and Company
Information provided by (Responsible Party):
Gilles Boire, Université de Sherbrooke
First received: August 3, 2007
Last updated: July 11, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||July 2016|
|Primary Completion Date:||July 2013 (Final data collection date for primary outcome measure)|
Roux S, Cabana F, Carrier N, Beaulieu M, April PM, Beaulieu MC, Boire G. The World Health Organization Fracture Risk Assessment Tool (FRAX) underestimates incident and recurrent fractures in consecutive patients with fragility fractures. J Clin Endocrinol Metab. 2014 Jul;99(7):2400-8. doi: 10.1210/jc.2013-4507.